AU775208B2 - Bicyclic compounds and their use as integrin receptor ligands - Google Patents

Bicyclic compounds and their use as integrin receptor ligands Download PDF

Info

Publication number
AU775208B2
AU775208B2 AU25617/00A AU2561700A AU775208B2 AU 775208 B2 AU775208 B2 AU 775208B2 AU 25617/00 A AU25617/00 A AU 25617/00A AU 2561700 A AU2561700 A AU 2561700A AU 775208 B2 AU775208 B2 AU 775208B2
Authority
AU
Australia
Prior art keywords
alkyl
compound according
compound
optionally substituted
prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU25617/00A
Other languages
English (en)
Other versions
AU2561700A (en
Inventor
David Edward Clark
Paul Robert Eastwood
Neil Victor Harris
Clive Mccarthy
Andrew David Morley
Stephen Dennis Pickett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis UK Holdings Ltd
Original Assignee
Aventis Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9903532.1A external-priority patent/GB9903532D0/en
Application filed by Aventis Pharma Ltd filed Critical Aventis Pharma Ltd
Publication of AU2561700A publication Critical patent/AU2561700A/en
Application granted granted Critical
Publication of AU775208B2 publication Critical patent/AU775208B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU25617/00A 1999-02-16 2000-02-16 Bicyclic compounds and their use as integrin receptor ligands Ceased AU775208B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9903532 1999-02-16
GBGB9903532.1A GB9903532D0 (en) 1999-02-16 1999-02-16 Chemical compounds
US14144599P 1999-06-29 1999-06-29
US60/141445 1999-06-29
PCT/GB2000/000553 WO2000049005A1 (en) 1999-02-16 2000-02-16 Bicyclic compounds and their use as integrin receptor ligands

Publications (2)

Publication Number Publication Date
AU2561700A AU2561700A (en) 2000-09-04
AU775208B2 true AU775208B2 (en) 2004-07-22

Family

ID=26315145

Family Applications (1)

Application Number Title Priority Date Filing Date
AU25617/00A Ceased AU775208B2 (en) 1999-02-16 2000-02-16 Bicyclic compounds and their use as integrin receptor ligands

Country Status (11)

Country Link
US (1) US6593354B2 (enExample)
EP (1) EP1153017B1 (enExample)
JP (1) JP2002537292A (enExample)
AT (1) ATE325105T1 (enExample)
AU (1) AU775208B2 (enExample)
CA (1) CA2362862A1 (enExample)
DE (1) DE60027700T2 (enExample)
DK (1) DK1153017T3 (enExample)
ES (1) ES2263447T3 (enExample)
PT (1) PT1153017E (enExample)
WO (1) WO2000049005A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0010599A (pt) * 1999-04-12 2002-02-13 Aventis Pharma Ltd Compostos de heteroarila bicìclicos substituìdos como antagonistas de integrina
GB9908355D0 (en) * 1999-04-12 1999-06-09 Rhone Poulenc Rorer Ltd Chemical compounds
GB0001346D0 (en) * 2000-01-21 2000-03-08 Astrazeneca Uk Ltd Chemical compounds
GB0004686D0 (en) * 2000-02-28 2000-04-19 Aventis Pharma Ltd Chemical compounds
US7157487B2 (en) 2000-12-28 2007-01-02 Daiichi Pharmaceutical Co., Ltd. Vla-4 inhibitors
US7351719B2 (en) 2002-10-31 2008-04-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds
ES2382806T3 (es) 2003-07-24 2012-06-13 Daiichi Sankyo Company, Limited Compuesto ácido ciclohexanocarboxílico
US7592373B2 (en) 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
DE10360745A1 (de) * 2003-12-23 2005-07-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
BRPI0508098A (pt) * 2004-02-27 2007-07-17 Amgen Inc compostos, composições farmacêuticas e métodos para uso no tratamento de distúrbios metabólicos
US7524862B2 (en) 2004-04-14 2009-04-28 Boehringer Ingelheim International Gmbh Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
DE102004017934A1 (de) 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US20070021612A1 (en) * 2004-11-04 2007-01-25 University Of Notre Dame Du Lac Processes and compounds for preparing histone deacetylase inhibitors and intermediates thereof
US7235688B1 (en) 2004-11-04 2007-06-26 University Of Notre Dame Du Lac Process for preparing histone deacetylase inhibitors and intermediates thereof
DE102006021878A1 (de) 2006-05-11 2007-11-15 Sanofi-Aventis Phenylamino-benzoxazol substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
UY32138A (es) * 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
UY32470A (es) 2009-03-05 2010-10-29 Boehringer Ingelheim Int Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
US8586604B2 (en) 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1
US8759537B2 (en) 2010-08-20 2014-06-24 Boehringer Ingelheim International Gmbh 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
US8674113B2 (en) 2010-12-10 2014-03-18 Boehringer Ingelheim International Gmbh Compounds
US8466186B2 (en) 2010-12-10 2013-06-18 Boehringer Ingelheim International Gmbh Compounds
US8486968B2 (en) 2010-12-10 2013-07-16 Boehringer Ingelheim International Gmbh Compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000005224A2 (en) * 1998-07-23 2000-02-03 Astrazeneca Ab Heterocyclic derivatives and their use as integrin inhibitor
AU5052199A (en) * 1998-07-23 2000-02-14 Astrazeneca Ab Chemical compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4025637A (en) 1973-10-23 1977-05-24 Lilly Industries, Ltd. 2,5 OR 2,6 Disubstituted benzoxazoles
US4100168A (en) 1974-09-20 1978-07-11 Lilly Industries Ltd. 2,5 OR 2,6-Disubstituted benzoxazoles
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
PT889877E (pt) * 1996-03-29 2002-02-28 Searle & Co Derivados fenileno meta substituidos e sua utilizacao como antagonitas ou inibidores integrina alfa v beta3
JPH10330369A (ja) 1997-04-04 1998-12-15 Sumitomo Pharmaceut Co Ltd 複素環化合物
GB9723789D0 (en) 1997-11-12 1998-01-07 Zeneca Ltd Chemical compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000005224A2 (en) * 1998-07-23 2000-02-03 Astrazeneca Ab Heterocyclic derivatives and their use as integrin inhibitor
AU5052199A (en) * 1998-07-23 2000-02-14 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
EP1153017A1 (en) 2001-11-14
DE60027700T2 (de) 2007-05-03
PT1153017E (pt) 2006-07-31
ATE325105T1 (de) 2006-06-15
DE60027700D1 (de) 2006-06-08
EP1153017B1 (en) 2006-05-03
AU2561700A (en) 2000-09-04
US20020137782A1 (en) 2002-09-26
US6593354B2 (en) 2003-07-15
JP2002537292A (ja) 2002-11-05
WO2000049005A1 (en) 2000-08-24
CA2362862A1 (en) 2000-08-24
DK1153017T3 (da) 2006-07-17
ES2263447T3 (es) 2006-12-16

Similar Documents

Publication Publication Date Title
AU775208B2 (en) Bicyclic compounds and their use as integrin receptor ligands
AU769554B2 (en) Substituted bicyclic heteroaryl compounds as integrin antagonists
AU754557B2 (en) Aza-bicycles which modulate the inhibition of cell adhesion
CA2370805C (en) Ureas as cell adhesion modulators
CA2372840C (en) Substituted bicyclic compounds
CA2449402C (en) Substituted tetrahydroisoquinolines for use in the treatment of inflammatory diseases
US20040006056A1 (en) Substituted alkanoic acids
CA2401441C (en) Indane derivatives
US6632814B1 (en) Dihydro-benzo(1,4)oxazines